Glaukos announces global licensing agreement with Intratus
Glaukos announced that it has entered into a licensing agreement with Intratus under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus' patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions. Intratus' patented cream-based drug formulations are applied to the outer surface of the eyelid for transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. Early human studies with this delivery system have demonstrated efficacy without the side effects often associated with drugs delivered as topical eye drops. Under the agreement, Glaukos will obtain an exclusive global license to Intratus' drug delivery technology for use in the treatment of glaucoma and corneal disorders, including dry eye disease, allergy, blepharitis, conjunctivitis and related conditions. Financial terms of the agreement were not disclosed.